Stock Quote
Provectus Pharmaceutical Inc (PVCT.OB) (OTC BB)
$1.00
25 Nov 2009
+1.01%
$1.00
--
44,885
$1.00
$0.97
$1.33
$0.68
1.40
125,699
No news stories for this company within the last 30 days.
PVCT.OB
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Dees, H. Craig | Chief Executive Officer, Director | 1,104,110 |
| Scott, Timothy | President, Director | 1,104,110 |
| Culpepper, Peter | Chief Financial Officer, Chief Operating Officer | 1,069,540 |
Profile
Provectus Pharmaceuticals, Inc., is a development-stage biopharmaceutical company that is focusing on developing invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including recurrent breast carcinoma, metastatic melanoma and liver cancer. The... Full Description
Company Address
Provectus Pharmaceutical Inc
7327 Oak Ridge Highway
Suite A
Knoxville TN 37931
P: +1865.7694011
7327 Oak Ridge Highway
Suite A
Knoxville TN 37931
P: +1865.7694011
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| QLT Inc. | $4.60 | -0.12 |
| DUSA Pharmaceuticals, Inc. | $1.52 | 0.00 |
| Johnson & Johnson | $63.30 | +0.12 |
| PVCT.OB | Industry | |
|---|---|---|
| P/E(TTM) | -- | 13.03 |
| P/S(TTM) | -- | 31.67 |
| ROI(TTM) | -102.39 | 2.43 |
| ROE(TTM) | -102.39 | 3.73 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -0.09 |
| Total Revenue | $0.00M |
| Net Income | $-4.01M |
| EPS | $-0.07 |
